Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New treatment for specific type of leukemia

11.05.2006
Leukemia - or cancer of the bone marrow - strikes some 700 Belgians each year. Chronic Eosinophilic Leukemia (CEL), a specific form of leukemia, is currently treated with Glivec.

However, recent research has shown that prolonged usage can cause resistance to Glivec, rendering this chronic form of leukemia untreatable. Researchers from the Flanders Interuniversity Institute for Biotechnology (VIB) connected to the Catholic University of Leuven have now discovered that another drug, Sorafenib (Nexavar), works on patients that have developed this resistance. This finding is not only important for CEL patients, but it also provides a new approach for treating specific forms of leukemia. It is clear from this research that a combination of targeted drugs provides a greater chance of lifelong effective treatment.

Chronic Eosinophilic Leukemia (CEL)
Our body’s white blood cells combat foreign intruders (such as viruses and bacteria). However, in chronic leukemia, the cells in the bone marrow that should develop into white blood cells multiply uncontrollably. These blood cells do not function properly, jeopardizing the production of normal blood cells. Among other consequences, this makes patients more susceptible to infections. Chronic leukemia appears in several forms - in CEL, a rare form of leukemia, the excessive increase of eosinophils (a certain type of white blood cell) can cause tissue damage in the heart, the skin, and the central nervous system.
The mechanism behind the cause
Under normal circumstances, our body regulates the production of white blood cells very precisely by means of a targeted activation of tyrosine kinases, which start this production. But sometimes defects in the DNA cause these tyrosine kinases to be active continuously, giving rise to diseases like leukemia. In 2003, Jan Cools and his colleagues under the direction of Peter Marynen, along with colleagues Elizabeth Stover and Gary Gilliland from Boston, discovered that CEL is caused by this kind of defective activation of the tyrosine kinase FIP1L1-PDGFRa. Now, with additional research, they have uncovered the molecular mechanism behind the abnormal activation of FIP1L1-PDGFRa. This new research is being published this week on the website of the scientific journal PNAS.
Resistance to the remedy
In the fight against CEL (and other forms of leukemia), scientists use proteins that inhibit the tyrosine kinases. Glivec is such an inhibitor and is effective against CEL because it specifically inhibits the activity of FIP1L1-PDGFRa. However, CEL patients must take Glivec every day for the rest of their lives - and recent research shows that, over time, alterations in the DNA can arise, causing resistance to Glivec. The longer Glivec is taken, the greater the chance resistance will develop. At that point, treatment with Glivec is no longer effective.
On the path to a long-lasting effective treatment
This problem prompted VIB researchers Els Lierman and Jan Cools to look for alternatives. They have found that Sorafenib, another inhibitor, works effectively in treating the resistant form of CEL. Sorafenib is already on the market in the US as a remedy for kidney tumors. This new research indicates that, to be able to treat certain forms of leukemia (like CEL) effectively over a long period of time, several inhibitors must be used, either together or successively. The scientists emphasize the importance of testing known inhibitors for their effectiveness against CEL and other forms of leukemia. This research has recently appeared in the scientific journal Blood.

Sooike Stoops | alfa
Further information:
http://www.vib.be

More articles from Life Sciences:

nachricht Cryo-electron microscopy achieves unprecedented resolution using new computational methods
24.03.2017 | DOE/Lawrence Berkeley National Laboratory

nachricht How cheetahs stay fit and healthy
24.03.2017 | Forschungsverbund Berlin e.V.

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>